Cappuzzo F, McCleod M, Hussein M, et al. IMpower130: progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. ESMO 2018, abstract LBA53.
Niet-selectieve bètablokkers geassocieerd met verlaagd HCC-risico bij cirrosepatiënten
dec 2021 | Hepatologie, Maag-darm-leveroncologie